Wall Street equity research analysts tracking AVITA Medical (RCEL) maintain twelve-month consensus price targets that generally fluctuate between $8.00 and $11.14 per share. These projections are updated regularly based on quarterly commercial execution, expanding hospital adoption rates, regulatory milestones for new label indications, and sequential revenue growth trends across international medical markets.